Combination Products Office Finalizing Manufacturing, Adverse Event Rules
This article was originally published in The Gray Sheet
Executive Summary
FDA says final rules on good manufacturing practices and adverse event reporting for combination products could be out as early as this fall.
You may also be interested in...
Device Industry Seeks More Clarity Following Combo Product GMP Final Rule
FDA’s final regulation outlines which manufacturing system requirements apply to products that have drug, device and/or biologic components. The Combination Products Coalition says key details need to be filled in by FDA with guidance.
Industry Seeks More Clarity Following Combo Product GMP Final Rule
FDA’s final regulation outlines which manufacturing system requirements apply to products that have drug, device and/or biologic components. An industry coalition says key details need to be filled in by FDA with guidance.
What's In A Name? FDA Offers More Clarity On The Device-Drug Dividing Line
Recognizing the blurred distinction between some advanced device and drug technologies, FDA has released a pair of draft guidance documents to clarify where certain medical products fall within the agency's regulatory scheme.